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ABSTRACT 
Background: Synuclein-γ (SNCG) is highly expressed in advanced solid tumors, 
including in uterine serous carcinoma (USC).  The goal was to determine if SNCG 
protein was associated with survival and clinical covariates using the largest existing 
collection of USC from the Gynecologic Oncology Group (GOG-8023).    
Methods: High-density tissue microarrays (TMAs) of tumor tissues of 313 patients with 
USC were stained by immunohistochemistry (IHC) for SNCG, p53, p16, FOLR1, pERK, 
pAKT, ER, PR, and HER2/neu. Association of SNCG and other tumor markers with 
overall and progression-free survival was assessed using Logrank tests and Cox 
proportional hazards models including adjustment for age, race, and stage. 
 Results: Overall survival at 5 years was 46% for high and 62% for low SNCG 
expression groups (logrank p=0.021, hazard ratio [HR]=1.31, 95% confidence interval 
[CI]= 0.91-1.9 in adjusted Cox model). Progression free survival at 5 years was worse for 
high SNCG at 40% compared to 56% for low SNCG (logrank p=0.0081,  [HR]=1.36, 95% 
[CI]= 0.96-1.92 in adjusted Cox model). High levels of both p53 and p16 were 
significantly associated with worse overall survival (p53: [HR]=4.20, 95% [CI]=1.54-
11.45;  p16:  [HR]= 1.95, 95% [CI]=1.01-3.75)  and progression-free survival (p53:  
[HR]= 2.16, 95% [CI]=1.09-4.27; p16:  ([HR]= 1.53, 95% [CI]=0.87-2.69) compared to 
low levels.  
Conclusions:  This is the largest collection of USC cases to date demonstrating that 
SNCG was associated with poor survival in USC in univariate analyses. SNCG does not 
predict survival outcome independently of p53 and p16 in models that jointly consider 
multiple markers. 
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BACKGROUND 
Endometrial carcinoma is the most common gynecologic malignancy in the 
United States with an estimated 54,870 cases in 2015 1.  Despite an overall good 
prognosis, survival varies dramatically depending upon the histologic subtype. Although 
uterine serous carcinoma (USC) accounts for about 10% of endometrial cancers, 
prognosis is substantially worse than the more common endometrioid adenocarcinoma, 
with frequent recurrences and high mortality rates 2, 3.  Active treatment modalities 
remain elusive as neither its pathogenesis nor the nature of its aggressive behavior and 
chemoresistance are well understood.  
Synuclein-γ (SNCG) has been demonstrated to be overexpressed in USC 4-6.  
SNCG is a member of the synuclein (SNC) family of proteins that are small, soluble, 
highly conserved neuronal proteins, implicated in both neurodegenerative diseases and 
cancer. SNCG overexpression occurs in multiple cancers including colon, gastric, 
pancreatic, ovarian, and lung cancer 7-14.  SNCG was first termed breast cancer-specific 
gene 1 (BCSG1) as it was shown to be correlated with poor prognosis and advanced 
stage in breast cancer 7, 10.  The mechanisms by which SNCG promotes advanced 
disease and chemoresistance have been shown to involve modulating the mitogen-
activated kinases (MAPKs), extracellular signal-regulated protein kinases 1/2 (ERK1/2) 
and c-Jun N-terminal kinase 1 (JNK1) 15.  Additionally, it has been demonstrated that 
SNCG interferes with paclitaxel-induced mitotic arrest by interacting with the mitotic 
checkpoint kinase BubR1 resulting in the inability of preventing cells with misaligned 
chromosomes from exiting mitosis 16.   Additional studies are necessary to define the 
role of SNCG in USC. 
We first identified SNCG expression specifically in USC through a pathway 
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focused expression array, followed by correlative analysis of SNCG expression with 
survival in 20 USC patients 6. While statistical significance was not reached due to a 
limited sample size, a trend for an association of SNCG with decreased progression-free 
survival was evident. In a larger study evaluating 279 endometrial carcinomas with 
varying histologies, of which 46 were USC, SNCG expression was positive in tumors 
with worse overall outcome, especially in clear cell, serous, and carcinosarcoma 
histologies 5. These data strongly suggest that SNCG may be a prognostic biomarker for 
USC.  
 The objective of this study was to determine if SNCG protein was associated with 
clinicopathologic variables and patient outcomes in a sufficiently large collection of USC 
tumors.  The associations of SNCG and other tumor markers, including p53 and p16, 
with multiple clinical parameters including survival were determined. This is the largest 
collection of USC cases to date representing 313 women with USC obtained from the 
Gynecologic Oncology Group (GOG), through its clinical trial programs.  
 
METHODS 
Patient Selection 
As described in the Gynecologic Oncology Group (GOG) study GOG-8023, 
women with USC who were eligible for and enrolled in GOG-0210 (a molecular staging 
study17), who had consented for future research and had histologically confirmed USC 
were included for TMA construction.  If there was insufficient tissue submitted on GOG 
210, then tissue collected on another study, GOG-0136 (a specimen banking study) was 
used.  The diagnosis of USC was reviewed for each case by the GOG Pathology 
Committee.  Research specimens were reviewed by the study pathologists to confirm 
that primary tumor consisted of at least 90% serous carcinoma.  The presence of any 
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non-serous histologic components was noted, but the histology in all cases was 
considered consistent with USC overall. 
Clinical data 
Overall survival was defined as observed length of life from study entry to death.  
Progression was defined as increasing clinical, radiologic, or histologic evidence of 
disease after study entry, and progression-free survival was defined as the time from 
study entry to the date of disease recurrence, progression, or death (whichever occurred 
first).  Lengths of follow-up from study entry until date of last contact for women without 
death or progression were treated as censored observations for overall survival and 
progression-free survival analyses, respectively. Types of adjuvant therapy were 
recorded using the following general terms: chemotherapy, radiation therapy, chemo-
radiation, hormonal therapy, other treatment regimen, or none.  Additional details were 
recorded when appropriate.  Other variables examined were age (at study entry), race, 
FIGO 1988 surgical stage (I-II vs. III-IV), presence or absence of lymphovascular space 
invasion, depth of myometrial invasion (none, <50%, ≥50%, serosal involvement), 
involvement of pelvic and/or para-aortic lymph nodes, and presence or absence of pelvic 
disease, abdominal disease, peritoneal disease and distant disease.  
Tissue Microarray 
A high-density tissue microarray (TMA) was created by the GOG Tissue Bank, 
which consisted of four 10x10 grids of 0.6 mm tissue cores, positioned as four quadrants 
on one microarray.  Each 10x10 grid included 90 randomly positioned USC patient 
tissues as well as 10 control tissues (5 normal human tissues, 5 human cancer tissues).  
Of the 90 tumors, 47 were represented in duplicate for a total of 313 patient tumors 
represented in the TMA.  There were four replicate tissue microarrays.  
Immunohistochemistry 
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Immunohistochemical (IHC) analyses were performed for the following 
biomarkers: SNCG, estrogen receptor (ER), progesterone receptor (PR), p53, HER2/neu, 
folate receptor 1 (FOLR1), p16, pAKT, and pERK.  Immunostains for all except 
HER2/neu were performed at the GOG Tissue Bank housed at the Biopathology Center, 
part of the Research Institute at Nationwide Children’s Hospital under the supervision of 
Dr. Nilsa Ramirez.  Immunostaining for HER2/neu was performed at the Pathology Core 
Facility of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 
under the supervision of Dr. Jian-Jun Wei.  The details for each antibody are 
summarized in Table 1.  All antibodies were tested on negative and positive control 
tissues provided by both the Northwestern Human Pathology Core and the GOG Tissue 
Bank.   
To validate the immunostains, each biomarker was also assessed in 
conventional blocks from 10% of the cases to confirm that the expression of each 
biomarker in the 0.6 mm cores was representative of the expression in full tissue 
sections.  A semiquantitative immunoreactivity for all markers was scored by two 
pathologists. All immunostains except HER2/neu were scored by intensity (1+, 2+, or 3+) 
and by percent of tumor cells staining (0, 1-10%, 11-20%, 21-30%, 31-40%, 41-50%, 51-
60%, 61-70%, 71-80%, 81-90%, 91-100%).  HER2/neu was scored as 0, 1+, 2+, or 3+ 
based on the 2007 scoring criteria established for breast cancer 18.  Marker definitions 
for each of the included biomarkers are delineated in Table 2.  For SNCG, intensity and 
percentage scores were initially combined into overall scores of low, medium, and high.  
The “low” category was defined as no staining (0%) or as 1+ intensity with ≤ 20% cells 
staining.  The “medium” category was defined as 1+ intensity with >20% cells staining, 
or 2-3+ intensity with 1-50% cells staining.  The “high” category was defined as 2-3+ 
intensity with >50% cells staining. For p53, “high” category was defined as >30% with 
any intensity or 0% labeling index (dead negative, indicative of null mutation). 
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The final immunoscores for SNCG, p53, and pAKT were given based on the 
most frequent score of quadruplicate tissue cores.  When this algorithm was 
inconclusive, the raw data were reviewed and a representative summary score was 
determined. For the remaining markers, only one TMA reading was performed. Upon 
initial analysis for SNCG staining, it was observed that survival curves were similar for 
“medium” and “high” groups.  Thus, these categories were combined into one “high” 
category, resulting in two SNCG expression groups (“low” and “high”) that were 
subsequently used for analysis. 
Power Considerations 
The study was originally designed to include three SNCG expression groups (low, 
medium, high).  Across a range of SNCG expression group distributions, a total sample 
size of 300 afforded 80% power at 5% two-sided Type I error and 10% loss-to-follow up 
to detect overall survival hazard ratios of 0.46-0.56 for low versus medium SNCG 
expression and 1.63-1.81 for high versus medium SNCG expression depending on the 
size of the low, medium and high groups 19.  A target sample size of 360 for TMA 
construction was set to allow for potential core loss.  In our analyses, due to similarity of 
effect estimates, the medium and high expression groups were combined for analysis.  
In post-hoc power calculations, our observed sample sizes in the SNCG expression 
groups yielded 80% power at 5% two-sided Type I error to detect a hazard ratio of 
roughly 1.62 for the high v. low SNCG expression group. 
Statistical Analysis 
Clinical and biomarker variables were summarized using the mean and standard 
deviation for age and tables of frequencies and counts for all other categorical variables.  
SNCG expression was the primary predictor of interest.  Analyses were initially 
conducted using three SNCG expression categories as planned.  Few differences in 
survival distributions and hazard functions were observed in all analyses for the original 
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medium and high expression groups, hence these two categories were combined and 
two SNCG expression groups (high vs low) were used for final analyses (Table 3). 
Secondary predictors of interest were expression of FOLR1, pERK, pAKT, p53, p16, ER, 
and PR (all high vs low), as well as HER2/neu expression (positive, negative, or 
equivocal). The primary outcome was overall survival (time in months) and the 
secondary outcome was progression-free survival (time in months).  
Age, race, surgical stage, presence of lymph-vascular space invasion, depth of 
myometrial invasion, pelvic and/or para-aortic lymph node involvement, pelvic disease, 
abdominal disease, peritoneal disease, distant disease, and adjuvant treatment were all 
summarized to describe the patient population and examined for association with SNCG 
expression using a t-test for age and chi-square or Fisher’s exact tests for categorical 
variables.  Clinical characteristics demonstrating association with SNCG expression 
group at p<0.05 were included in Cox proportional hazards models to assess potential 
confounding in SNCG associations with time to event outcomes.  
Kaplan-Meier curves for overall survival and progression-free survival were 
generated for both SNCG groups.  Logrank tests were used to assess differences 
between the curves.   Cox proportional hazards models were used to estimate hazard 
ratios and adjustments for age, race and stage were examined in Cox models.  The 
same process was used for all tumor markers of secondary interest.  Hazard ratios were 
estimated in multiple marker models for SNCG and p16 as well as SNCG and p53.  
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RESULTS 
SNCG in Uterine Serous Carcinoma 
USC tumors from patients enrolled in GOG-0210, were collected and tissue 
microarrays were constructed by the GOG Tissue Bank 
(http://www.nationwidechildrens.org/biopathology-center-collaborations).  Clinical data 
and adequate tissue specimens were available for analysis from 313 patients.  
Immunostaining for SNCG revealed a variable extent (focal/patchy to extensive/diffuse) 
and intensity of staining, localized predominantly to the cytoplasm of tumor cells with 
occasional nuclear staining (Fig 1). The staining was categorized as high and low based 
on intensity of staining and the percentage of cells stained (Table 2; low=0-1 intensity 
with <20% of tumor cells staining; high= 2-3 intensity or >20% of tumor cells staining).  
High expression of SNCG was seen in 61.8% of cases (Table 3). The mean age at 
diagnosis was statistically significantly different with 67.2 years for low and 69.8 years 
for high SNCG expression (p = 0.01; Table 4).  Surgical stage, histologic heterogeneity, 
the presence of lymphovascular space invasion, depth of myometrial invasion, pelvic 
and para-aortic lymph node metastasis, the presence of pelvic, abdominal, peritoneal or 
distant disease, and the type of adjuvant treatment were similar across the SNCG 
groups. While no differences in SNCG expression were observed according to race or 
stage, these covariates were included along with age in adjusted models due to known 
associations with overall survival. 
In unadjusted analyses, overall survival was statistically significantly worse for 
women whose tumors demonstrated high SNCG expression (Fig 2, Table 5, logrank test 
p=0.021).  At 5 years, the overall survival estimates were 62% for those with low SNCG 
expressing cancers and 46% for those with high expression of SNCG.  The association 
between SNCG and overall survival was attenuated in adjusted Cox models with a 
hazard ratio of 1.31 (95% CI: 0.91-1.9, p=0.15) after adjusting for age, race and stage.  
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Progression-free survival was also statistically significantly lower for women with tumors 
that had high SNCG expression in unadjusted analyses (Fig 2, Table 5; logrank test, 
p=0.0081).  At 3 years, 63% of women with low SNCG expression were progression-free 
compared to 47% of women with high expression.  This was also seen at 5 years with a 
progression-free survival of 56% and 40% for low and high SNCG groups, respectively. 
The Cox model hazard ratio adjusted for age, race, and stage favored low SNCG 
expression (HR = 1.36 for high v. low expression, 95% CI 0.96-1.92, p=0.086).  The 
Kaplan–Meier plots illustrate lower survival for high SNCG compared to low SNCG 
expression (Fig 2).   Trends were similar when survival was examined for white race and 
black race separately (Suppl Fig 1).  
Association of other tumor markers in USC 
We next sought to determine the expression pattern of other known molecular 
markers in endometrial cancer and associations with progression and survival outcomes.  
The TMAs were stained for p53, p16, FOLR1, pERK, pAKT, PR, ER, and HER2/neu and 
scored as high or low (Suppl Fig 2, Suppl Fig 3, Table 3).   As summarized in Table 3, 
more than 50% of the patients had high immunoreactivity of SNCG, p53, p16, and 
FOLR1.  HER2/neu was positive in only 2.2% of USC cases and negative in over 95% of 
these samples.  Less than 20% of cases exhibited high immunoreactivity for pERK and 
pAKT while the majority (> 80%) had low levels.  Both ER and PR immunoreactivity were 
low in more than half of the cases.   
Among the markers tested, only p53 and p16 were significantly associated with 
unfavorable clinical outcomes.  Women whose cancer demonstrated high p53 
expression had worse overall survival (HR=4.2, 95% CI 1.54-11.45, p=0.005) and 
disease progression (HR=2.16, 95% CI 1.09-4.27, p=0.027) (Table 6A). Trends were 
also evident for tumors with high p16 expression associated with worse overall survival  
(HR=1.95, 95% CI 1.01-3.75, p=0.046) and progression free survival (HR=1.53, 95% CI 
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0.87-2.69, p=0.14) (Table 6A). Expression levels of p16 and p53 were associated with 
each other with about 92% of tumors with high p53 expression also demonstrating high 
p16 expression (p<0.0001).  Cox models using multiple markers were also examined to 
determine whether the association of SNCG with overall survival and progression-free 
survival was independent of p53 and p16 associations.  In Cox models including SNCG 
and p53 as well as age, race, and stage, associations of SNCG with the outcomes were 
attenuated and no longer statistically significant, with hazard ratio of 1.19 (95% CI 0.81-
1.73, p=0.37) for overall survival and 1.27 (95% CI 0.89-1.81, p=0.19) for progression-
free survival.   When SNCG and p16 were included in a model together, associations 
with overall and progression-free survival were attenuated and not statistically significant 
for both markers.  Nevertheless, over 90% of high SNCG tumors also had high p53 
and/or p16 expression (Table 6B). The expression of FOLR1, pERK, pAKT, PR, and ER 
and the hazard ratios for these markers were not statistically significant (Table 7).   
 
DISCUSSION 
The incidence of USC is rare accounting for only 10% of newly diagnosed 
endometrial cancers.  It is, however, one of the most aggressive tumors of the 
endometrium, with high recurrence and associated mortality rates 2, 3. Active treatment 
modalities remain elusive, as neither its pathogenesis nor its chemoresistance is well 
understood.  A third to one half of USC tumors are admixed with other histologic 
subtypes,20 although recent literature based on data from The Cancer Genome Atlas 
indicates that the morphologic reproducibility of carcinomas with mixed or ambiguous 
histology is poor, and POLE-ultramutated endometrioid carcinomas in particular may be 
morphologically misdiagnosed as USC 21, 22. Notwithstanding this newer data, however, 
morphology-based studies have found that even when the USC component contributes 
as little as 10% to the tumor, its behavior can resemble pure serous carcinoma 23. A 
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significant limitation to studying USC is the small number of cases that can be collected 
at any one institution.  The Gynecologic Oncology Group with the cooperation of multiple 
centers has collected thousands of endometrial cancer samples through various clinical 
trial protocols.    Specifically, USC tumor specimens used in this study were collected 
and banked as part of the clinical trials, GOG-0210 and GOG-0136.    As a result, 313 
USC cases with adequate tumor represented on the TMA and detailed clinical 
information were available for this study, representing the largest collection of USC 
tumors with corresponding clinical information available for investigation to date. The 
statistical study design planned the sample size to have 80% statistical power at 5% 
Type I error with 10% loss to follow-up to detect hazard ratios of 0.46-0.56 for low versus 
medium SNCG expression and 1.63-1.81 for high versus medium SNCG expression in 
the original three group design.  The study results revealed a statistically significant 
association between SNCG expression and overall as well as progression-free survival 
in univariate analyses. In addition, given the size of this cohort, standardized criteria for 
a relatively reliable cut-off score for SNCG to allow for interpretation of immunoreactivity 
for SNCG could be established. Consistent with a recent study 4, a score of low and high 
expression of SNCG is a reproducible approach to interpreting IHC score of SNCG in 
USC. Further validation of technical methodology and interpretation criteria will be 
needed before widespread adoption of SNCG IHC staining as a diagnostic or prognostic 
marker.   
According to our study, the survival of women with high expression of SNCG was 
worse, despite no statistically significant association between SNCG expression and 
certain clinical parameters at the time of a uterine serous carcinoma diagnosis, including 
stage, depth of myometrial invasion, lymphovascular space invasion, and nodal 
metastasis. Unadjusted analyses demonstrated a statistically significant association 
between SNCG expression and overall and progression-free survival, although 
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associations were attenuated after adjustment for age, race and stage.  Additional 
investigations with larger sample size may clarify associations since observed hazard 
ratios for both time-to-event outcomes in these data were slightly lower than those we 
were adequately powered to detect. USC is an aggressive malignancy with early intra-
abdominal and retroperitoneal spread even in the absence of traditional risk factors, 
such as deep myometrial invasion, tumor size, and lymphovascular space invasion (3).  
Thus SNCG may be associated with mechanisms related to this unique spread pattern.  
However, there is still much to be learned regarding the genes and pathways that permit 
metastasis preferentially into the abdominal and peritoneal cavities.   
Molecular studies have implicated SNCG to be involved in chemoresistance. It 
was shown that SNCG bound to a spindle checkpoint kinase, BubR1, thereby inducing a 
structural change of BubR1.  This inhibited its kinase activity as well as attenuated its 
interaction with other key checkpoint proteins such as Cdc20, compromising the spindle 
assembly checkpoint 16, 24, 25.  The lack of checkpoint function would allow cells to 
override G2/M arrest with aneuploidy proliferation to perpetuate genomic instability. By 
targeting SNCG with a specific peptide, sensitivity to paclitaxel was enhanced 26.  
Association of SNCG with clinical chemoresistance was not assessed in this study due 
to insufficient information and remains an unanswered question.  Most women in this 
study received some form of adjuvant therapy and the distribution of chemotherapy, 
pelvic radiotherapy, or both were similar in both the low and high SNCG expression 
groups. The use of SNCG as a marker for chemoresistance is a plausible option that 
should be explored.   
The association of SNCG with other tumor markers was examined in this study.  
Among the markers tested, only p53 and p16 were associated with overall survival and 
progression-free survival.  To our knowledge, this is the largest cohort that demonstrates 
the association of p53 or p16 with survival in USC, providing evidence of the prognostic 
Page 17 of 36 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 17
potential of these two markers.   Only one study demonstrated p53 to be significantly 
associated with worse survival in 34 cases of USC  27 while association studies of p16 
and survival in USC have not been reported, underscoring the relevance of our study of 
313 cases of USC.  High versus low expression of the other markers, pAKT, pERK, ER, 
PR, and FOLR1, was not significantly associated with survival.  The expression of pAKT, 
pERK, ER, PR, and FOLR1 has been studied extensively in endometrioid carcinoma, 
but their role in USC is less understood. ER has been shown to associate with SNCG 
which increases transcriptional activity of ER to mediate estrogen driven proliferation in 
the mammary gland 28-30.  SNCG can stimulate membrane-initiated estrogen signaling to 
stimulate growth and promote tamoxifen resistance in breast cancer cells 30.  The data 
as to whether ER contributes to the aggressive nature of USC are sparse even though 
USC is distinct from endometrioid adenocarcinoma with regards to hormone-
dependence.  An analysis of 71 USC cases in Japan demonstrated an overall and 
progression-free survival advantage with positive hormone receptor status 31.   However, 
in our study, neither ER nor PR was associated with survival outcomes. In our study, we 
grouped IHC staining for ER and PR as high versus low expression whereas the 
Japanese study compared hormone positive (either ER or PR are expressed) versus 
negative for either ER or PR.  Nevertheless, in our study, 40% and 36% of USC cases 
expressed high levels of ER and PR, respectively.  It remains to be studied whether ER 
and PR actively influence USC behavior.  Signaling pathways including AKT and MAPK 
have been implicated in driving metastasis and chemoresistance in tumors 32-36 and, 
therefore, were markers of interest in this study. Moreover, SNCG has been shown to 
maintain pAKT and mTOR activities protecting cells from the cytotoxicity related to 
disabling Hsp90 37. Similarly, SNCG protected HER2/neu function rendering it resistant 
to Hsp90 mediated toxicity 38.  In this study, although each of these markers was not 
independently associated with survival, it is possible they may play a role in resistance to 
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treatments as chemoresistance was not part of the analysis in this study. HER2/neu is 
amplified in a wide range of cases from 10% to 65% depending on the study 39-42.  In our 
study, staining of HER2/neu was low.  Of note, this study employed breast cancer 
criteria for scoring HER2/neu expression in USC, as specific criteria for scoring 
HER2/neu in USC have not yet been established. One study reported that screening for 
HER2/neu with IHC overestimated the number of cases showing HER2/neu gene 
amplification as there was significant discordance between IHC and in situ hybridization 
43
.  Clinical relevance of HER2/neu in USC is also not entirely clear as some studies 
have shown association with poor overall survival in patients with type II endometrial 
cancer and specifically USC 39, 44 while others have demonstrated no association with 
survival 41.  Survival analysis for HER2/neu expression could not be done in this study 
due to the low number of tumors that exhibited staining.   Additional testing with in situ 
hybridization staining along with IHC would be a more accurate measure of the positive 
cases.   
In summary, this study demonstrated a statistically significant association of 
SNCG with poor survival outcomes in USC in unadjusted analyses, with some 
attenuation of the association after adjustment for age, race and stage. Levels of p53 
and p16 were also significantly associated with worse survival.  In analyses of multiple 
markers, SNCG did not demonstrate statistically significant association after adjustment 
for p53 or p16; hence, these data do not support SNCG as an independent predictor of 
survival outcomes. However, the association of SNCG with markers of advanced 
disease merit further investigation of its role in USC biology or as a predictive biomarker.  
Unlike p53 or p16, SNCG has been detected in the serum of patients harboring tumors 9, 
14, 45, 46
.  A serum biomarker along with other tumor markers could aid in earlier diagnosis 
or recurrence.   Additionally, the role of SNCG in predicting chemoresistance remains to 
be studied. Finally, this study reports the largest collection of USC cases with clinical 
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information showing that SNCG, p53 and p16 are associated with worse survival 
outcome.  This resource can be used to study other promising tumor marker candidates 
for this rare uterine cancer. 
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FIGURE LEGENDS 
Figure 1:  Immunohistochemical staining of SNCG in tumor cores in the USC TMA.   
Two representative sections of A,B) high and C,D) low expression are shown. Brown 
color represents positive SNCG staining. 
 
Figure 2: Kaplan–Meier survival curves for patients with USC stratified according to A) 
SNCG, B) p53 and C) p16 expression (high versus low). Statistically and clinically 
significant differences were observed between the groups for both overall survival and 
progression-free survival.   
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Table 1: Antibody assay characteristics 
 
Antibody Source Clone Dilution Antigen 
Retrieval 
SNCG Abcam EP1539Y 
 
1:500 TRS 
ER Dako 1D5 1:600 TRS 
PR Dako PgR 636 1:10 TRS 
p53 Dako DO-7 1:50 TRS 
HER2/neu Dako A0485 
Polyclonal 
1:1000 Decloaking 
chamber, 
pH6 
p16 Ventana E6H4 1:600 CC1 
P(S473)-AKT Abcam  Polyclonal 1:100 TRS 
p(Y204)-ERK  Abcam Polyclonal 1:200 TRS 
FOLR1 Leica Microsystems BN3.2 1:50 EDTA 
 
TRS:  Target Retrieval Solution,  
CC1:  Cell Condition 1;  
EDTA:  Ethylenediaminetetraacetic acid 
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Table 2: Marker expression pattern definitions 
 
Marker Expression pattern definitions (%, intensity) Expression 
patterns 
included 
High expression Medium 
expression 
Low expression 
SNCG >20%, 2+/3+ >20%, 1+, or 
1-50%, 2+/3+ 
≤ 20%, 0/1+ Cytoplasmic 
+ Nuclear 
ER >10%, any 
intensity 
NA 0%, or 
≤10%, any 
intensity 
Nuclear 
PR >10%, any 
intensity 
NA 0%, or 
≤10%, any 
intensity 
Nuclear 
p53 >30%, any 
intensity, 
or 
0% labeling index 
NA - 1-30%, any 
intensity 
 
Nuclear 
p16 >50%, any 
intensity 
NA ≤50%, any 
intensity 
Nuclear + 
cytoplasmic 
pAKT >50%, 1+, or 
>20%, 2+/3+ 
NA ≤50%, 1+, or 
≤20%, 2+/3+ 
Membranous 
+ 
cytoplasmic 
pERK >50%, 1+, or 
>20%, 2+/3+ 
NA ≤50%, 1+, or 
≤20%, 2+/3+ 
Nuclear + 
cytoplasmic 
FOLR1 >10%, any 
intensity 
NA ≤10%, any 
intensity 
Membranous 
HER2/neu* Positive (Score 
3+) 
Equivocal (Score 
2+) 
Negative (Score 0 
or 1+) 
Membranous 
*Scoring for Her2/neu was based on the 2007 scoring criteria recommended for breast 
cancer [15] 
NA=not applicable 
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Table 3: Marker expression frequencies 
 Low 
n (%) 
High 
n (%) 
Total 
 
SNCG 115 (38.2%) 186 (61.8%) 301 
p53 42 (13.6%) 267 (86.4%) 309 
p16 35 (12.2%) 252 (87.8%) 287 
FOLR1 104 (37.0%) 177 (63.0%) 281 
pERK 237 (82.0%) 52 (18.0%) 289 
pAKT 264 (85.7%) 44 (14.3%) 308 
PR 184 (63.5%) 106 (36.6%) 290 
ER 171 (59.2%) 118 (40.8%) 289 
 
 
 Negative n(%) Equivocal n(%) Positive n(%)  
HER2/neu^ 299 (95.5%) 7 (2.2%) 7 (2.2%) 313 
^Since the sample sizes for HER2/neu are so small, survival analyses are not reported. 
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 Table 4: Patient characteristics   
 
 All Patients  
n=313 
Low SNCG 
n=115 
High SNCG  
n=186 
p-value* 
Age in years (mean and sd) 68.7 (8.6) 67.2 (9.0) 69.8 (8.1) 0.01 
     
Race     
     White 217 
(74.3%)  
88 (79.3%) 
129 
(71.3%) 
0.33 
     Black 70 (24.0%) 22 (19.8%) 48 (26.5%)  
     Other 5 (1.7%) 1 (0.9%) 4 (2.2%)  
     
FIGO 1988 Surgical Stage     
     Stage 1-2 154 
(49.2%) 
61 (53.0%) 85 (45.7%) 0.22 
     Stage 3-4 159 
(50.8%) 
54 (47.0%) 
101 
(54.3%) 
 
     
Diagnostic Pathology Review 
Classification 
    
     Pure Serous Carcinoma 239 
(76.4%) 
83 (72.3%) 
145 
(78.0%) 
0.18 
     Serous with Endometrioid   
     Features (indeterminate) 
42 (13.4%) 15 (13.0%) 26 (14.0%)  
     Other 32 (10.2%) 17 (14.8%) 15 (8.1%)  
     
Malignant cells in vascular 
lymphatic space 
    
     Absent 169 
(55.0%) 
65 (58.0%) 97 (53.0%) 0.40 
     Present 138 
(45.0%) 
47 (42.0%) 86 (47.0%)  
     
Depth of myometrial invasion     
     None 64 (20.9%) 16 (14.2%) 42 (23.1%) 0.25 
     <50% 119 
(38.8%) 
50 (44.3%) 66 (36.3%)  
     >50% 105 
(34.2%) 
41 (36.3%) 63 (34.6%)  
     Serosa 19 (6.2%) 6 (5.3%) 11 (6.0%)  
     
Pelvic and/or paraaortic nodal 
metastisis 
    
     None 177 
(63.2%) 
76 (69.7%) 
101 
(59.1%) 
0.15 
     Pelvic only 37 (13.2%) 10 (9.2%) 27 (15.8%)  
     Paraaortic with or without   
     positive pelvic nodes 
66 (23.6%) 23 (21.1%) 43 (25.2%)  
     
Pelvic disease     
     No 210 
(71.4%) 
87 (77.7%) 
123 
(67.6%) 
0.06 
     Yes 84 (28.6%) 25 (22.3%) 59 (32.4%)  
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Abdominal disease     
     No 222 
(81.6%) 
85 (86.7%) 
137 
(78.7%) 
0.10 
     Yes 50 (18.4%) 13 (13.3%) 37 (21.3%)  
     
Peritoneal disease     
     No 210 
(70.2%) 
86 (74.8%) 
124 
(67.4%) 
0.17 
     Yes 89 (29.8%) 29 (25.2%) 60 (32.6%)  
     
Distant disease     
     No 151 
(98.0%) 
54 (98.2%) 91 (97.9%) 1.00 
     Yes 3 (2.0%) 1 (1.8%) 2 (2.2%)  
     
Adjuvant treatment     
     Chemotherapy 122 
(51.1%) 
46 (50%) 70 (51.1%) 0.40 
     Radiation 27 (11.3%) 8 (8.7%) 19 (13.9%)  
     Chemotherapy and 
radiation 
90 (37.7%) 38 (41.3%) 48 (35.0%)  
*P-values are for comparisons of characteristics across low and high SNCG expression 
groups.  Student’s t-test was used for comparison of age.  All other categorical 
comparisons were evaluated using chi-square tests, except for depth of myometrial 
invasion and distant disease, which used Fisher’s exact test. 
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Table 5: SNCG expression and survival estimates 
 
SNCG  n  
(n events) 
 
Overall survival  
Logrank 
p-value 
Hazard Ratio 
(95% CI, p) 
  1-year 3-years 5-years 
0.021 
1.31 
(0.91-1.9, 0.15) High 186 (93) 0.89 0.66 0.46 
Low 115 (43) 0.94 0.73 0.62 
   
Progression-free survival  
 
  
  1-year 3-years 5-years 
0.0081 
1.36 
(0.96-1.92, 
0.086) 
High 186 (109) 0.77 0.47 0.40 
Low 115 (49) 0.81 0.63 0.56 
 
Overall and progression-free survival estimates were evaluated based on high and low 
SNCG expression levels with a logrank test.  The hazard ratio compared high versus low 
SNCG expression and is adjusted for age, race, and stage with a 95% confidence 
interval and p value. 
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Table 6A:  p53 and p16 expression relationship to survival 
 n  
(n events) 
 
Overall survival  
Logrank 
p-value 
Hazard Ratio 
(95% CI, p) 
  1-year 3-years 5-years 
0.0008 
4.20 
(1.54-11.45, 
0.005) 
p53 High 267 (130) 0.90 0.66 0.48 
Low 42 (9) 0.95 0.86 0.80 
 
p16 High 252 (124) 0.90 0.66 0.48 0.016 1.95 
(1.01-3.75, 0.046) Low 35 (10) 0.94 0.83 0.70 
   
Progression-free survival  
  
  1-year 3-years 5-years 
0.0092 
2.16 
(1.09-4.27, 0.027) p53 High 267 (147) 0.78 0.50 0.42 
Low 42 (15) 0.81 0.76 0.71 
 
p16 High 252 (141) 0.76 0.50 0.43 0.048 1.53 
(0.87-2.69, 0.14) Low 35 (14) 0.89 0.69 0.58 
Overall and progression free survival estimates based on high and low p53 and p16 
expression with a logrank test.  The hazard ratio compared high versus low expression 
and is adjusted for age, race, and stage with a 95% confidence interval and p value. 
 
 
 
 
 
 
Table 6B:  Associations between significant markers 
 p53 
Low 
p53 
High 
  p16 
Low 
p16 
High 
  p16 
Low 
p16 
High 
SNCG  
Low 
23  
(0.20) 
92 
(0.80) 
SNCG  
Low 
24 
(0.22) 
84 
(0.78) 
p53 
Low 
19 
(0.54) 
16 
(0.46) 
SNCG 
High 
16 
(0.09) 
170 
(0.91) 
SNCG  
High 
11 
(0.06) 
168 
(0.94) 
p53 
High 
19 
(0.08) 
233 
(0.92) 
 p=.00042  p<.0001  p<.0001 
Data represent counts.  The values in parentheses are row percentages.  P values 
indicate whether association between high and low expression of pairs of markers is 
statistically significant  
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Table 7: Hazard ratios for the additional markers 
HR  FOLR1 pERK pAKT PR ER 
OS 1.04 
(0.72-1.51, 
0.84) 
1.10 
(0.68-1.76, 
0.70) 
1.00 
(0.63-1.58, 
0.99) 
0.82 
(0.57-1.19, 
0.30) 
0.92 
(0.65-1.32, 
0.66) 
PFS 1.16 
(0.81-1.64, 
0.42) 
1.22 
(0.80-1.85, 
0.37) 
1.09 
(0.73-1.65, 
0.67) 
.78 
(0.55-1.09, 
0.15) 
.90 
(0.65-1.25, 
0.52) 
The hazard ratio compared high versus low expression of each marker and is adjusted 
for age, race, and stage with a 95% confidence interval and p value. 
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Figure 1  
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Figure 2  
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